M8
M8W.F MediWound Ltd
- Market cap
- EUR 165M
- P/E
- -
- P/B
- 5.50x
- ROE
- -58.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is M8W.F undervalued?
Graham numberThe Graham number of MediWound Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
MediWound Ltd fundamental analysis
No fundamental analysis for MediWound Ltd yet.
MediWound Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About MediWound Ltd
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bio…
Full company profileMediWound Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
MediWound Ltd annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.56M | 2.50M | 3.40M | 31.8M | 21.8M | 23.8M | 26.5M | 18.7M | 20.2M | 17.0M | 9.13M |
| Gross Profit | -600K | 918K | 1.31M | 19.9M | 7.55M | 8.77M | 13.2M | 3.58M | 2.63M | 3.25M | 1.32M |
| Operating Income | -20.2M | -13.7M | -11.5M | 4.49M | -8.84M | -11.2M | -7.66M | -15.5M | -19.4M | -25.3M | -34.9M |
| EBITDA | - | -13.1M | -4.20M | 4.14M | -7.35M | -11.4M | -6.39M | -4.80M | -27.9M | -21.5M | -33.3M |
| Net Income | -18.9M | -22.1M | -1.06M | 4.96M | -9.20M | -13.6M | -19.6M | -6.72M | -30.2M | -23.9M | -20.7M |
| EPS | - | -0.82 | -0.04 | 0.18 | -0.34 | -0.50 | -2.71 | -0.73 | -2.80 | -1.86 | -1.60 |
| Balance Sheet | |||||||||||
| Total Assets | 35.8M | 44.1M | 35.3M | 40.6M | 31.1M | 19.7M | 50.0M | 66.5M | 73.5M | 86.3M | 71.9M |
| Total Liabilities | 28.0M | 34.5M | 26.3M | 25.4M | 23.8M | 24.3M | 39.1M | 34.9M | 42.3M | 42.6M | 36.2M |
| Shareholders' Equity | 7.77M | 9.62M | 8.97M | 15.2M | 7.27M | -4.58M | 10.9M | 31.6M | 31.2M | 43.6M | 35.6M |
| Cash & Short-term Investments | 28.9M | 36.1M | 6.72M | 7.24M | 17.4M | 11.0M | 33.9M | 11.9M | 9.16M | 4.80M | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -16.4M | -16.5M | -12.2M | 8.29M | -6.90M | -8.92M | -11.9M | -10.5M | -13.6M | -16.1M | -31.8M |
| Capital Expenditure | 701K | 1.05M | 522K | 792K | 923K | 489K | 555K | 6.46M | 6.27M | 5.51M | 5.79M |
| Free Cash Flow | - | -17.5M | -12.7M | 7.50M | -7.82M | -9.41M | -12.4M | -16.9M | -19.9M | -21.6M | -37.6M |
| Ratios | |||||||||||
| ROE | -243.1% | -230.2% | -11.8% | 32.7% | -126.5% | - | -179.6% | -21.3% | -97.0% | -54.7% | -58.0% |
| ROA | -52.8% | -50.2% | -3.0% | 12.2% | -29.6% | -68.6% | -39.2% | -10.1% | -41.1% | -27.7% | -28.8% |
| Net Profit Margin | -1,212.1% | -887.4% | -31.1% | 15.6% | -42.3% | -57.0% | -74.0% | -35.9% | -149.5% | -140.8% | -226.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
MediWound Ltd dividends
MediWound Ltd has not paid dividends in the last 9 fiscal years.
Last stock split: 1:7 on Dec 20, 2022.
Who owns MediWound Ltd
- Insiders 15.26%
- Institutions 50.92%
- Public & others 33.83%
- Shares outstanding 14.4M
- Free float 9.26M
MediWound Ltd company profile
- Company name
- MediWound Ltd
- Ticker
- M8W.F
- ISIN
- IL0011316309
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 121
- Fiscal year end
- December
- Address
- 42 Hayarkon Street, Yavne, Israel, 8122745
- Phone
- 972 7 797 14100
- Website
- mediwound.com
About MediWound Ltd
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bioactive enzymatic therapy for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
MediWound Ltd management
8- Mr. Ofer Gonen B.Sc.Chief Executive Officer · born 1973
- Ms. Hani LuxenburgChief Financial Officer · born 1974
- Dr. Shmulik Hess Ph.D.COO & Chief Commercial Officer · born 1974
- Mr. Yaron Meyer Adv.Executive VP, General Counsel & Corporate Secretary · born 1979
- Dr. Ety Klinger MBA, Ph.D.Chief Medical Officer · born 1962
- Dr. Liron GalVice President of Manufacturing Science & Technology
- Mr. Barry J. WolfensonExecutive Vice President of Strategy & Corporate Development · born 1967
- Dr. Robert J. Snyder CWS, D.P.M., F.A.C.F.A.S., FFPM, M.B.A., M.Sc.Senior Vice President of Global Medical Affairs · born 1951